Bank Of New York Mellon Corp Century Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$3.4 - $5.11 $203,908 - $306,462	59,973 New	59,973 $208 Million
Q4 2022 Feb 14, 2023	BUY	$4.84 - $11.58 $291,639 - $697,764	60,256 New	60,256 $309,000
Q3 2022 Nov 14, 2022	BUY	$8.57 - $13.1 $90,910 - $138,964	10,608 Added 22.4%	57,957 $573,000
Q2 2022 Aug 15, 2022	BUY	$7.96 - $12.43 $27,605 - $43,107	3,468 Added 7.9%	47,349 $398,000
Q1 2022 May 11, 2022	BUY	$11.62 - $15.92 $122,288 - $167,542	10,524 Added 31.55%	43,881 $552,000
Q4 2021 Feb 11, 2022	BUY	$13.93 - $23.62 $61,640 - $104,518	4,425 Added 15.29%	33,357 $529,000
Q3 2021 Nov 12, 2021	BUY	$20.8 - $31.93 $601,785 - $923,798	28,932 New	28,932 $727,000

36.9M

8.7K

10.2K

Ticker IPSC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,881,800
Market Cap $61.8M
Description
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.